openPR Logo
Press release

Chest experts Oxipit and contextflow team up for diagnostic quality assurance

07-18-2022 04:39 PM CET | Health & Medicine

Press release from: Oxipit

The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit's ChestEye Quality and contextflow's SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center.

ChestEye Quality analyzes medical images and corresponding radiologist reports. Acting as a virtual safety net, the software sends a notification to the radiologist if it detects a mismatch or a missed finding not identified in the radiologist report.

ChestEye Quality can operate in retrospective and prospective settings, providing quality audit notifications in near-real time. The product is already deployed in more than 10 medical institutions worldwide.

Out of nearly 200,000 analyzed chest X-ray images, an average of 1 in 552 (0.18%) chest X-ray studies feature clinically-significant missed findings. The result varies from 0.08% to 0.92% depending on the type of medical institution. 78% of the missed findings relate to pulmonary nodules, aiding earlier detection of lung cancer and significantly improving patient treatment prognosis.

The contextflow partnership will expand ChestEye Quality capabilities into the CT modality.

contextflow SEARCH Lung CT is a clinical decision support system that automatically detects, quantifies and visualizes key disease patterns and lung nodules in CTs of the lungs over time, displaying relevant information directly in the radiologist's PACS viewer. The tool is relevant for the analysis of many suspected diseases, including interstitial lung disease (ILD), chronic pulmonary obstructive disease (COPD), and lung cancer.

In a clinical impact study at the Medical University of Vienna (MUW), an earlier version of SEARCH Lung CT showed an average reading time savings of 31% when contextflow SEARCH Lung CT is available for use with a trend towards improved diagnostic accuracy. The study was recently published in European Radiology.

"We are excited to partner with experts in CT AI medical imaging. The ChestEye Quality AI double reading approach has already proven itself in the CXR modality, helping radiologists to spot more clinically-relevant nodules and improving early diagnostics of lung cancer. Collaboration with contextflow highlights the robustness of the ChestEye Quality framework, showcasing how the AI double reader approach can be easily expanded into other medical imaging modalities," says Oxipit CEO Gediminas Peksys.

contextflow Chief Commercial Officer Marcel Wassink continues: "Radiologists tell me they are often extremely busy or even exhausted towards the end of their shift. Reading lung CTs is a complicated task, whereby even the most experienced radiologists have only moderate consensus. Therefore they can't deny they may sometimes oversee early signs of a disease in the scan or oversee or misjudge relevant patterns, which is supported by scientific publications. With this cooperation we aim to provide radiologists a safety net that catches potential mismatches between the contents in the radiology report and the visual findings related to all patterns in the CT scan detected by contextflow. The goal is to further support radiologists with a friendly warning system that helps them double check their analysis of the CT scan."
The first ChestEye CT Quality deployment is planned at the Leiden University Medical Center (LUMC).

"In the domain of chest X-ray and CT imaging, we have been successfully working with both Oxipit and contextflow for several years, with their applications integrated in the radiology workflow and in use in daily clinical practice. We are looking forward to having the quality functionality expanded to cover chest CT imaging with the goal of further improving the quality of care for our patients," notes Head of Imaging Services Group at LUMC Dr Willem Grootjans.

Oxipit
Sauletekio al. 15-1, LT-10224
Vilnius, Lithuania
www.oxipit.ai

About Oxipit | www.oxipit.ai
Oxipit develops AI applications for diagnostic medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative artificial intelligence breakthroughs to everyday clinical practice.

About contextflow | www.contextflow.com
contextflow is a spin-off of the Medical University of Vienna (MUW) and European research project KHRESMOI, supported by the Technical University of Vienna (TU). Founded by a team of AI and engineering experts in July 2016, the company has received numerous awards; most recently, contextflow was named a Born Global Champion 2021 by the Austrian Chamber of Commerce. Its clinical decision support software SEARCH Lung CT is CE Marked and available for clinical use within Europe under the new MDR.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chest experts Oxipit and contextflow team up for diagnostic quality assurance here

News-ID: 2683150 • Views:

More Releases from Oxipit

Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
03-02-2023 | Health & Medicine
Oxipit
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company's products. "CARPL is our
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
02-15-2023 | Health & Medicine
Oxipit
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency's approval is one of Oxipit steps to increase global reach for company products. "With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
01-23-2023 | Health & Medicine
Oxipit
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital and Practica Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom. "2022 was a breakthrough year for the Oxipit team. In spring we introduced ChestLink - the first fully
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
11-21-2022 | Health & Medicine
Oxipit
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month. Oxipit Quality employs AI as the second reader for quality assurance.

All 5 Releases


More Releases for ChestEye

11-24-2021 | Health & Medicine
Oxipit
Oxipit to offer free of charge retrospective CXR quality audit at RSNA
At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data. ChestEye Quality is already deployed in multiple medical institutions across Europe. With 229.617 images processed, the platform helped to identify 20% extra clinically relevant nodules, as well as numerous missed
05-25-2020 | Health & Medicine
Oxipit
Oxipit Receives Patent for Improved AI Lung Cancer Diagnostics
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection. Modern X-ray equipment produces large images with 16 Megapixel resolution being common. On the other hand, machine learning and artificial intelligence (AI) algorithms are typically optimized
03-05-2020 | Health & Medicine
Oxipit
Oxipit ChestEye secures medical device certification in Australia
The AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries. "Australia presents a very advanced, well developed healthcare landscape.
01-29-2020 | Health & Medicine
Oxipit
New Oxipit service to aid large scale chest X-ray screening projects
The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects. "Large scale medical surveys - such as tuberculosis screening in migrant populations
11-26-2019 | Health & Medicine
Oxipit
AI vs Radiologists: can AI surpass doctors in reporting accuracy?
A study by the Centre for Advanced Research in Imaging, Neuroscience and Genomics (CARING) found that nearly 80% of AI generated chest X-ray case reports were as accurate as produced by a radiology specialist. Furthermore, AI reports were more accurate in 5% of analyzed patient cases. The study was undertaken using Oxipit ChestEye AI imaging suite. The full study titled The full study titled “Judging the Accuracy and Clinical Validity
07-23-2019 | Health & Medicine
Oxipit
Medical Imaging Company Oxipit raises $1.7M Seed Round to bring AI into Clinical …
Oxipit are the authors of ChestEye AI-powered radiology software suite. Automated AI-based diagnosis and reporting by ChestEye enables radiologists to improve productivity, reduce error-rate, discover overlooked secondary findings and address the shortage and ever-increasing workload of radiology specialists. The round marks the largest investment for medical AI solutions in the Baltic states. It is also one of the largest seed rounds among Baltic startups. In February ChestEye software received CE